The group’s principle activities include designing and developing novel topical eyedrop products for ophthalmology, oncology and inflammatory diseases. The group's eye drop prodcts OT-551 and OT-730 to treat age related diseases. The group’s OT-300 series of compounds are used for cancer, thrombosis and inflammatory diseases. The group operates from United States.